From IgE to clinical trials of allergic rhinitis

Giorgio Ciprandi, Gian Luigi Marseglia, Riccardo Castagnoli, Chiara Valsecchi, Carlotta Tagliacarne, Silvia Caimmi, Amelia Licari

Research output: Contribution to journalArticlepeer-review


The current scientific research is continuously aiming at identifying new therapeutic targets with the purpose of modifying the immune response to allergens. The evolution in immunological methods has led to the identification of immunoglobulin E (IgE) as both a diagnostic biomarker and potential therapeutic target in allergic diseases, such as allergic rhinitis. Allergen immunotherapy has been used for more than 100 years to treat allergic diseases and it is today considered the only disease-modifying treatment capable of inducing a long-lasting immunological and clinical tolerance toward the causal allergen. During the past 20 years, major advances have been made in understanding the molecular and cellular mechanisms of allergen tolerance in humans. Moreover, there has been considerable progress in allergen extract modifications and additions to standard extracts. The recognition that IgE plays a pivotal role in basic regulatory mechanisms of allergic inflammation has recently stimulated research into the therapeutic potential of directly targeting this antibody. Omalizumab, the most advanced humanized anti-IgE monoclonal antibody, is currently approved for the treatment of uncontrolled allergic asthma and chronic spontaneous urticaria. Interesting results also arise from studies in which omalizumab was administered in patients with allergic rhinitis. The aim of this review is to provide an update on current findings on immunological and clinical effects of allergen immunotherapy and anti-IgE therapy, which have been shown to have synergistic modes of action for the treatment of allergic rhinitis.

Original languageEnglish
Pages (from-to)1321-1333
Number of pages13
JournalExpert Review of Clinical Immunology
Issue number12
Publication statusPublished - Dec 2 2015


  • allergen immunotherapy
  • allergic rhinitis
  • IgE
  • omalizumab
  • sublingual immunotherapy

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'From IgE to clinical trials of allergic rhinitis'. Together they form a unique fingerprint.

Cite this